Johnson & Johnson Stock Forecast for 2023 - 2025 - 2030
Updated on 02/01/2023
Johnson & Johnson Stock Forecast and Price Target
Johnson & Johnson's most recent price target of $180.50 for 2023 was provided by six renowned analysts over the past few months, with an average prediction of $180.50. If this prediction is correct, Johnson & Johnson's stock could rise by 10.45 percent from its current trading price. The potential increase for the stock is $180.50 per share, with a possible range of $164.00 to $215.00. Even if you are not interested in JNJ stock, you should still be aware of its competitors.
10.45% Upside
Johnson & Johnson Fair Value Forecast for 2023 - 2025 - 2030
Johnson & Johnson's Price has decreased In the last four years, from $145.28 to $121.83 – a 16.14% drop. In the next year, analysts predict that Fair Value will reach $193.94 – an increase of 59.18%. For the next eight years, the forecast is for Fair Value to grow by 89.50%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$344.15 | $333.19 | 16.23% |
| PFE Stock Forecast | Pfizer Inc | Outperform |
3
|
$44.16 | $53.97 | 19.23% |
| VRTX Stock Forecast | Vertex Pharmaceuticals Inc | Outperform |
16
|
$323.10 | $323.74 | 0.90% |
| ZTS Stock Forecast | Zoetis | Buy |
18
|
$165.49 | $207.87 | 23.87% |
| ALNY Stock Forecast | Alnylam Pharmaceuticals | Outperform |
7
|
$226.40 | $244.18 | 10.87% |
Johnson & Johnson Revenue Forecast for 2023 - 2025 - 2030
Johnson & Johnson's Revenue has grown in the last four years, jumping from $81.58B to $94.94B – an increase of 16.38%. In the next year, analysts predict that Revenue will reach $100.28B – an increase of 5.62%. For the next eight years, the forecast is for Revenue to grow by 10.90%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| BAX Stock Forecast | Baxter International | Outperform |
17
|
$45.69 | $62.83 | 26.94% |
| VTRS Stock Forecast | Viatris | Outperform |
8
|
$12.15 | $13.70 | 11.11% |
| UTHR Stock Forecast | United Therapeutics | Outperform |
12
|
$263.17 | $279.92 | 12.09% |
Johnson & Johnson Dividend per Share Forecast for 2023 - 2025 - 2030
In the last four years, Johnson & Johnson's Dividend per Share has increased by 27.68%, going from $3.54 to $4.52. In the next year, analysts are expecting an increase in Dividend per Share, predicting it will reach $4.63 – an increase of 2.43%. The Johnson & Johnson forecast is for Dividend per Share to reach $5.75 or grow by 27.21%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| CTLT Stock Forecast | Catalent | Outperform |
15
|
$53.55 | $76.00 | 36.32% |
| IONS Stock Forecast | Ionis Pharmaceuticals | Outperform |
9
|
$39.87 | $52.42 | 25.41% |
| CYTK Stock Forecast | Cytokinetics | Outperform |
10
|
$42.45 | $62.07 | 41.34% |
Johnson & Johnson Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last four years, Johnson & Johnson's Free Cash Flow has fallen from $18.53B to $17.00B – a 8.28% decrease. In the next year, analysts expect Free Cash Flow to reach $26.97B – an increase of 58.68%. For the next eight years, the forecast is for Free Cash Flow to grow by 71.64%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| BCPC Stock Forecast | Balchem | Outperform |
18
|
$130.63 | $163.67 | 25.55% |
| NEOG Stock Forecast | Neogen | Hold |
16
|
$21.42 | $37.00 | 19.05% |
| CORT Stock Forecast | Corcept Therapeutics | Outperform |
16
|
$22.86 | $0.00 | 29.05% |
Johnson & Johnson Net Income Forecast for 2023 - 2025 - 2030
In the last four years, Johnson & Johnson's Net Income has grown, increasing from $15.30B to $17.94B – an increase of 17.28%. For next year, the 17 analysts predict Net Income of $28.77B, which would mean an increase of 60.37%. Over the next eight years, the pros' prediction is Net Incomeof $29.27B, which would mean a eight-year growth forecast of 63.15%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| INDV Stock Forecast | Indivior PLC | Buy |
14
|
£182.10 | £3.79 | -97.40% |
| PCRX Stock Forecast | Pacira BioSciences | Outperform |
16
|
$39.25 | $79.67 | 98.73% |
| AMPH Stock Forecast | Amphastar Pharmaceuticals | Outperform |
14
|
$30.25 | $41.00 | 45.45% |
Johnson & Johnson EBITDA Forecast for 2023 - 2025 - 2030
In the last four years, Johnson & Johnson's EBITDA has decreased from $28.10B to $24.02B – a 14.52% drop. The next year looks promising for Johnson & Johnson, with analysts predicting EBITDA of $36.70B – an increase of 52.76%. Over the next eight years, experts anticipate that Johnson & Johnson's EBITDA will grow at a rate of 63.85%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| IRWD Stock Forecast | Ironwood Pharmaceuticals | Hold |
14
|
$11.52 | $12.60 | 8.51% |
| SUPN Stock Forecast | Supernus Pharmaceuticals | Outperform |
16
|
$41.02 | $35.50 | -17.11% |
| LGND Stock Forecast | Ligand Pharmaceuticals | Outperform |
14
|
$69.70 | $195.43 | 127.40% |
Johnson & Johnson EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Johnson & Johnson's EBIT has grown by 19.23%, from $21.18B to $25.25B. For the next year, analysts are expecting EBIT to reach $33.15B – an increase of 31.29%. Over the next eight years, experts predict that EBIT will grow by 68.35%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| MDGL Stock Forecast | Madrigal Pharmaceuticals | Outperform |
4
|
$288.07 | $170.08 | -39.25% |
| USNA Stock Forecast | USANA Health Sciences | Hold |
14
|
$58.44 | $104.00 | -2.46% |
| NasdaqCM:ARPO Stock Forecast | Aerpio Pharmaceuticals | - |
6
|
$27.92 | $0.00 | 10.35% |
Johnson & Johnson EPS Price Prediction Forecast for 2023 - 2025 - 2030
Johnson & Johnson's EPS has decreased In the last four years, from $8.18 to $6.86 – a 16.14% drop. In the next year, analysts predict that EPS will reach $10.92 – an increase of 59.18%. For the next eight years, the forecast is for EPS to grow by 89.50%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| CPRX Stock Forecast | Catalyst Pharmaceuticals | Outperform |
16
|
$15.49 | $10.95 | -22.53% |
| TGTX Stock Forecast | TG Therapeutics | Outperform |
9
|
$15.23 | $73.38 | 24.75% |
| INVA Stock Forecast | Innoviva | Hold |
16
|
$12.65 | $10.00 | 26.48% |